Thursday, February 27, 2014

Fresenius Kabi sets up new $47 million pharmaceutical manufacturing centre in Melbourne to provide lifesaving products to patients

Fresenius Kabi sets up new $47 million pharmaceutical manufacturing centre in Melbourne to provide lifesaving products to patients
 
Construction is set to begin on a state of the art Australian pharmaceutical manufacturing facility that will deliver lifesaving infusion therapies, irrigation solutions, I.V generic drugs and compounded oncology products to public and private hospital patients Australia wide.
 
The facility will be built on a 40,000 square metre site by Fresenius Kabi Australia, one of the major pharmaceutical and medical devices providers to hospitals in the country. The new site will create 120 jobs after entering full operation.
 
Marking the start of construction, Zita Peach, Managing Director of Fresenius Kabi Australia & New Zealand and Executive Vice President South Asia Pacific said, “The site will markedly change the landscape for IV products and oncology delivery in Australia. Up until now there has been limited choice for hospitals when it comes to choosing products that are manufactured locally. This site will see products being manufactured that have easy handling, drug compatibility, sterility and environmental characteristics.
 
“The investment in this site demonstrates the strength of our commitment to Australian manufacturing and is great news for patients, hospital staff and the greater community who will all benefit.” said Zita Peach.
 
It will also secure local manufacturing of IV solutions using the Fresenius Kabi freeflex® infusion bag, a high quality, flexible, DEHP-free, latex-free and PVC-free container, which means reduced exposure to patients and environment
 
“Fresenius Kabi Australia currently provides infusion therapies, irrigation solutions and compounded oncology products to patients in over 180 public and private hospitals and clinics throughout Australia. This new facility will enable the availability of more medicines to more people, ultimately improving patient outcomes,” said Zita Peach.
continue to read here

No comments: